Literature DB >> 23877677

Structures of the class D Carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam.

Kip-Chumba J Kaitany1, Neil V Klinger, Cynthia M June, Maddison E Ramey, Robert A Bonomo, Rachel A Powers, David A Leonard.   

Abstract

Class D β-lactamases that hydrolyze carbapenems such as imipenem and doripenem are a recognized danger to the efficacy of these "last-resort" β-lactam antibiotics. Like all known class D carbapenemases, OXA-23 cannot hydrolyze the expanded-spectrum cephalosporin ceftazidime. OXA-146 is an OXA-23 subfamily clinical variant that differs from the parent enzyme by a single alanine (A220) inserted in the loop connecting β-strands β5 and β6. We discovered that this insertion enables OXA-146 to bind and hydrolyze ceftazidime with an efficiency comparable to those of other extended-spectrum class D β-lactamases. OXA-146 also binds and hydrolyzes aztreonam, cefotaxime, ceftriaxone, and ampicillin with higher efficiency than OXA-23 and preserves activity against doripenem. In this study, we report the X-ray crystal structures of both the OXA-23 and OXA-146 enzymes at 1.6-Å and 1.2-Å resolution. A comparison of the two structures shows that the extra alanine moves a methionine (M221) out of its normal position, where it forms a bridge over the top of the active site. This single amino acid insertion also lengthens the β5-β6 loop, moving the entire backbone of this region further away from the active site. A model of ceftazidime bound in the active site reveals that these two structural alterations are both likely to relieve steric clashes between the bulky R1 side chain of ceftazidime and OXA-23. With activity against all four classes of β-lactam antibiotics, OXA-146 represents an alarming new threat to the treatment of infections caused by Acinetobacter spp.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23877677      PMCID: PMC3811470          DOI: 10.1128/AAC.00762-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa.

Authors:  F Danel; L M Hall; D M Livermore
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

2.  Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs.

Authors:  Xiaojun Wang; George Minasov; Brian K Shoichet
Journal:  J Mol Biol       Date:  2002-06-28       Impact factor: 5.469

Review 3.  Minor extended-spectrum beta-lactamases.

Authors:  T Naas; L Poirel; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

4.  Protein structure prediction on the Web: a case study using the Phyre server.

Authors:  Lawrence A Kelley; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

5.  Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme.

Authors:  Michiyoshi Nukaga; Kayoko Mayama; Andrea M Hujer; Robert A Bonomo; James R Knox
Journal:  J Mol Biol       Date:  2003-04-18       Impact factor: 5.469

6.  OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.

Authors:  G Bou; A Oliver; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Three factors that modulate the activity of class D β-lactamases and interfere with the post-translational carboxylation of Lys70.

Authors:  Lionel Vercheval; Cédric Bauvois; Alexandre di Paolo; Franck Borel; Jean-Luc Ferrer; Eric Sauvage; André Matagne; Jean-Marie Frère; Paulette Charlier; Moreno Galleni; Frédéric Kerff
Journal:  Biochem J       Date:  2010-12-15       Impact factor: 3.857

8.  Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Authors:  Sarah M Drawz; Maja Babic; Christopher R Bethel; Magda Taracila; Anne M Distler; Claudia Ori; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  33 in total

1.  The structure of a doripenem-bound OXA-51 class D β-lactamase variant with enhanced carbapenemase activity.

Authors:  Cynthia M June; Taylor J Muckenthaler; Emma C Schroder; Zachary L Klamer; Zdzislaw Wawrzak; Rachel A Powers; Agnieszka Szarecka; David A Leonard
Journal:  Protein Sci       Date:  2016-09-26       Impact factor: 6.725

2.  Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Tiffany R Keepers; Marcela Gomez; Chris Celeri; Wright W Nichols; Kevin M Krause
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Kinetic characterization of GES-22 β-lactamase harboring the M169L clinical mutation.

Authors:  Aysegul Saral; David A Leonard; Azer Ozad Duzgun; Aysegul Copur Cicek; Cynthia M June; Cemal Sandalli
Journal:  J Antibiot (Tokyo)       Date:  2016-05-11       Impact factor: 2.649

4.  Structural Basis for Enhancement of Carbapenemase Activity in the OXA-51 Family of Class D β-Lactamases.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Nichole K Stewart; Hilary Frase; Marta Toth; Katherine A Kantardjieff; Sergei Vakulenko
Journal:  ACS Chem Biol       Date:  2015-06-12       Impact factor: 5.100

5.  OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains.

Authors:  Yunxing Yang; Qingye Xu; Tingting Li; Ying Fu; Yue Shi; Peng Lan; Dongdong Zhao; Qiong Chen; Zhihui Zhou; Yan Jiang; Anton Y Peleg; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.

Authors:  Juan Carlos Vázquez-Ucha; María Maneiro; Marta Martínez-Guitián; John Buynak; Christopher R Bethel; Robert A Bonomo; Germán Bou; Margarita Poza; Concepción González-Bello; Alejandro Beceiro
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Common clinical substitutions enhance the carbapenemase activity of OXA-51-like class D β-lactamases from Acinetobacter spp.

Authors:  Joshua M Mitchell; David A Leonard
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

8.  Clinical Variants of the Native Class D β-Lactamase of Acinetobacter baumannii Pose an Emerging Threat through Increased Hydrolytic Activity against Carbapenems.

Authors:  Emma C Schroder; Zachary L Klamer; Aysegul Saral; Kyle A Sugg; Cynthia M June; Troy Wymore; Agnieszka Szarecka; David A Leonard
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

9.  Crystal structure of carbapenemase OXA-58 from Acinetobacter baumannii.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Marta Toth; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  A fluorescent carbapenem for structure function studies of penicillin-binding proteins, β-lactamases, and β-lactam sensors.

Authors:  Cynthia M June; Robert M Vaughan; Lucas S Ulberg; Robert A Bonomo; Laurie A Witucki; David A Leonard
Journal:  Anal Biochem       Date:  2014-07-21       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.